• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $JUNS

    Jupiter Neurosciences Inc.

    Subscribe to $JUNS
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Jupiter Neurosciences Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Jupiter Neurosciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

      PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, proje

      6/30/25 3:15:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science

      GLO targets the growing "beauty-from-within" market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, is pleased to unveil Nugevia™ GLO—a pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellular science. GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration. Unmatched Scienc

      6/27/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

      Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Annika Sörenstam, the most accomplished female professional golfer in history, has joined the Company as the first official brand ambassador for Nugevia™, Jupiter Neurosciences' new consumer longevity supplement line. Annika, who has amassed over 95 international tournament victories—including 72 LPGA titles and 10 major championships—will collaborate with the Company to champion Nugevia's science-backed formulations designed for performance, f

      6/23/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science

      First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia's debut comes as global demand accelerates for scientifically validated wellness soluti

      6/9/25 7:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter

      Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™ JOTROL™ development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure Jupiter, Florida, April 08, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the release of its first shareholder letter as a publicly traded company. The letter from Chairman and CEO Christer Rosén outlines the Company's 2025 strategic roadmap, including key clinical and commercial

      4/8/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products

      First three consumer products expected to launch in Q3 2025, providing near-term revenue growth Jupiter, Florida, March 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Aquanova AG to jointly develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. "As we explore new ways to translate our scientific discoveries into tangible health solutions, we see an immense opportunity in the longevity and healthspan market," said Christer Rosén, Chairman & CEO of

      3/4/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

      Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials. "The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have been no undisclosed material developmen

      2/4/25 9:25:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial

      Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced it has entered into an agreement with Catalent Pharma Solutions, LLC ("Catalent") for the production of JOTROL™ softgel capsules to support Jupiter's upcoming Phase 2a clinical trial in Parkinson's disease. Under the terms of the agreement, Catalent will manufacture clinical batches of JOTROL, Jupiter's proprietary resveratrol-based therapeutic, using an optimized softgel formulation. The production will include both active and placebo batches for the Pa

      2/3/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial

      Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Zina Biopharmaceuticals, LLC ("Zina") to support all aspects of Jupiter's upcoming Phase 2a clinical trial for Parkinson's disease. Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL™, Jupiter's patented resveratrol-based therapeutic platform. The primary objective of the trial will be to evaluate the safety and tolerability o

      1/30/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

      Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims to unlock new therapeutic potential for neurodegenerative diseases, longevity, and aging, positioning the Company at the forefront of innovation in neuroinflammation treatments. The NLRP3 inflammasome is a key inflammation driver linked to central nervous system (CNS) disorders, metabolic diseases, and aging-related conditions. JOTROL, Jupiter's flagshi

      1/13/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Jupiter Neurosciences Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer converted options into 973,466 shares and bought $7,986 worth of shares (7,816 units at $1.02), increasing direct ownership by 10% to 11,075,292 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:50 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Jupiter Neurosciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer converted options into 973,466 shares and bought $7,986 worth of shares (7,816 units at $1.02), increasing direct ownership by 10% to 11,075,292 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:50 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Weis Holger converted options into 10,781 shares (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      1/24/25 2:33:53 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brady Allison W converted options into 21,750 shares (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      1/24/25 2:31:28 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Jupiter Neurosciences Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Jupiter Neurosciences Inc.

      10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      5/15/25 4:31:24 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Jupiter Neurosciences Inc.

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      4/21/25 12:38:15 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Jupiter Neurosciences Inc.

      10-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      3/28/25 5:01:29 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      3/25/25 5:16:25 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Jupiter Neurosciences Inc.

      10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      12/23/24 4:46:40 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      12/20/24 7:00:15 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      12/19/24 5:00:18 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      12/4/24 4:57:34 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care